Science

This can be a short description about this vertical and all the great links contained therein.

R&D Strategy

Evidence

Pipeline

Clinical Trials

Article originally published February 2026 […]

Learn More ›

Products

This can be a short description about this vertical and all the great links contained therein.

Sepsis ImmunoScore®

First-ever FDA authorized AI sepsis diagnostic tool with powerful diagnostic and predictive capabilities

5th World Sepsis Congress  |  […]

Learn More ›

Resources

This can be a short description about this vertical and all the great links contained therein.

Resource Library

Events

Sepsis ImmunoScore® demonstrates stronger predictive […]

Learn More ›

Newsroom

Read the latest Prenosis peer-reviewed articles and items from scholarly journals.

Newsroom

Sepsis ImmunoScore® demonstrates stronger predictive […]

Learn More ›

About

Read the latest Prenosis peer-reviewed articles and items from scholarly journals.

Mission, Vision, Values

Careers

Leadership

Awards

AI in Chicago  |  Episode […]

Learn More ›

Transforming Sepsis Care with AI: Prenosis Delivers Innovation

Labcorp Knowledge Library  |  Series  |  Brief Interviews with Healthcare Innovators

Interview originally published on Labcorp Knowledge Library September 19, 2025

Prenosis CEO and co-founder, Bobby Reddy, Jr. outlines the company’s mission to improve patient lives by tailoring healthcare to each person’s biology in this post as part of Labcorp’s Brief Interviews with Healthcare Innovators series, highlighting innovative companies in the Labcorp Venture Fund portfolio.

Jim Almas, MD, vice president and national medical director for clinical effectiveness, spoke with Bobby Reddy Jr., PhD, co-founder and CEO of Prenosis, a trailblazing startup that uses AI to redefine the standard of care for critical conditions.

Read the full interview >